Premium
Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers
Author(s) -
Le Blanc Gabriella,
Jetté Pomerleau Vincent,
McCarthy Jillian,
Borroni Barbara,
Swieten John,
Galimberti Daniela,
SanchezValle Raquel,
LaForce Robert,
Moreno Fermin,
Synofzik Matthis,
Graff Caroline,
Masellis Mario,
Tartaglia Maria C.,
Rowe James B.,
Vandenberghe Rik,
Finger Elizabeth,
Tagliavini Fabrizio,
Mendonça Alexandre,
Santana Isabel,
Butler Chris,
Gerhard Alex,
Danek Adrian,
Levin Johannes,
Otto Markus,
Frisoni Giovanni,
Sorbi Sandro,
Rohrer Jonathan D.,
Ducharme Simon
Publication year - 2020
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.25748
Subject(s) - c9orf72 , frontotemporal dementia , atrophy , dementia , asymptomatic , magnetic resonance imaging , asymptomatic carrier , trinucleotide repeat expansion , age of onset , psychology , medicine , pathology , allele , genetics , biology , disease , radiology , gene
Objective C9orf72 expansion is the most common genetic cause of frontotemporal dementia (FTD). We examined aging trajectories of cortical thickness (CTh) and surface area in C9orf72 expansion adult carriers compared to healthy controls to characterize preclinical cerebral changes leading to symptoms. Methods Data were obtained from the Genetic Frontotemporal Dementia Initiative. T1‐weighted magnetic resonance imaging scans were processed with CIVET 2.1 to extract vertex‐wide CTh and cortical surface area (CSA). Symptomatic and presymptomatic subjects were compared to age‐matched controls using mixed‐effects models, controlling for demographic variables. Aging trajectories were compared between carriers and noncarriers by testing the “age by genetic status” interaction. False discovery rate corrections were applied to all vertex‐wide analyses. Results The sample included 640 scans from 386 subjects, including 54 symptomatic C9orf72 carriers (72.2% behavioral variant FTD), 83 asymptomatic carriers, and 249 controls (age range = 18–86 years). Symptomatic carriers showed fairly symmetric reduction in CTh/CSA in most of the frontal lobes, in addition to large temporoparietal areas. Presymptomatic subjects had reduced CTh/CSA in more restricted areas of the medial frontoparietal lobes, in addition to scattered lateral frontal, parietal, and temporal areas. These differences were explained by faster cortical thinning linearly throughout adulthood in a similar anatomical distribution, with differences emerging in the early 30s. CSA reduction was also faster in mutation carriers predominantly in the ventrofrontal regions. Interpretation C9orf72 mutation carriers have faster cortical thinning and surface loss throughout adulthood in regions that show atrophy in symptomatic subjects. This suggests that the pathogenic effects of the mutation lead to structural cerebral changes decades prior to symptoms. ANN NEUROL 2020 ANN NEUROL 2020;88:113–122